Learn More & Connect With Our Team
Let's Work Together
HAI Solutions is a clinical-stage medical device company dedicated to revolutionizing intravenous care and aiming to reduce hospital-acquired infections through innovative technologies like the QIKcap System. As a C-Corp advancing FDA-authorized solutions with manufacturing ramp-up and commercial partnerships underway, we are focused on delivering meaningful improvements in patient safety and clinical outcomes.
We welcome accredited investors and strategic partners who share our vision for transforming vascular access and infection prevention. This page provides an overview of our mission, progress, and opportunities—it is for informational purposes only and does not constitute an offer to sell or solicitation to buy securities.
Our Team Is
• Mission-Driven Innovation: Developing the QIKcap System (FDA De Novo granted) and complementary vascular access devices to combat contamination in IV therapy, targeting significant reductions in bloodstream infections (BSIs) across hospitals, ICUs, and beyond.
• Strong Leadership & Expertise: Supported by a team of experienced advisors in medtech, regulatory affairs, and infection prevention.
• Market Opportunity: Addressing a large and growing need in the vascular access and hospital-acquired infection prevention markets, with a subscription-based model designed for scalable adoption and recurring revenue.
• Key Milestones: FDA De Novo grant for the QIKcap System, ISO 13485 certification, manufacturing ramp, successful Series A close, and active outreach to strategic partners and distributors.
• Growth Stage: Raising capital to fuel commercialization, GTM expansion, and further innovation. We are pursuing strategic partnerships, non-dilutive funding, and long-term value creation for patients, clinicians, and stakeholders.
• Why Partner With Us: Backed by clinical insights, a robust IP portfolio, and a clear path to market leadership in a critical healthcare segment.